TiumBio Announces First Patient Dosed in Phase 2 Clinical Trial of Oral Immuno-Oncology Drug TU2218
- Written by PR Newswire
 |
- TU2218 is a potentially first-in-class dual inhibitor targeting transforming growth factor beta receptor 1 (TGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2)
- The first patient with head and neck squamous cell carcinoma was dosed in the Phase 2a clinical trial of TU2218
- The Phase 2a trial of TU2218 starts with head and neck squamous...
